Cancer research has been experiencing a revolution in a sense. The industry has been producing many more powerful medications than in years of the past. These technologically advanced facilities are placed all around the world, but the United States is home to one of the leaders in this exclusive class. Located in Bothell, Washington, is Seattle Genetics, and it epitomizes the term revolutionary science. The biotech company has 20 years under its belt, and it has grown each and every year. CEO Clay Siegall is the captain of the ship, and he has at least 30 years of experience in the game.
Siegall is probably one of the most celebrated and accomplished professionals in cancer research. The guy has a resume that others dream about having, but he has always remained humble. Siegall is a published author, he has written up to 70 publications, and he holds well-over 15 patents. Yes, this guy is the real deal, but he isn’t completely satisfied with his success. In some form or fashion, everyone has seen cancer’s effects or has dealt with cancer in one way or another. Siegall has introduced some very strict rules and regulations for conducting business. When it comes to a person’s health, time is of the essence. Copious amounts of information is being recorded at a consistent rate and scientific innovation is the catalyst. When these two components are combined, great things are about to transpire.
Seattle Genetics has many distribution deals thanks to Siegall because he was able to secure multiple deals with top pharmaceutical companies. Pfizer and Bayer are just two of the high-profile names. The old-guard of cancer research has come full-circle, and it has saved many lives. Siegall uses every aspect of his educational background in Zoology and from Genetics. Cancer may not be totally eradicated, but’s has definitely seen better days, which is a good thing.
Dr. Clay Siegall is leading the new wave of targeted cancer therapies. Perhaps a few years from now we will be looking at the Seattle Genetics founder and CEO as a legend in cancer treatment. He officially co-founded the Seattle based biotech company in 1998. Since then it has become a leader in providing advanced anti-body conjugates for cancer treatment. The company’s immediate goal is to vastly improve the mortality rate of cancers that have seen no substantial improvements in decades.
Seattle Genetics is responsible for developing the first FDA-approved antibody drug conjugate. Even more impressive it has partnered with multiple drug manufacturers to roll out its impressive string of drugs. Its partners includes prominent manufacturers such as Bayer and Genentech.
When Dr. Clay first founded Seattle Genetics many professionals thought it wouldn’t make it past the startup phase. Although Dr. Clay and Seattle Genetics exceeded those expectations those who doubted all those years ago had reason. At the time it was just a tiny startup with a small team of researchers. Despite its humble beginnings Dr. Clay always had big plans for the company’s future. Seattle Genetics is continually expanding its list of drugs while simultaneously adding more to the development pipeline.
Dr. Clay founded came up with the idea to start Seattle Genetics after a family member was diagnosed with cancer and he was unsatisfied with the chemotherapy treatment. Because of this it is his belief that systematic chemotherapy is soon to be outdated and targeted therapies are the future.
Before founding Seattle Genetics Dr. Clay Siegall he worked as a researcher at various medical organizations. he worked at the National Cancer Institute for 3 years before departing and joining Bristol-Myers Squibb Pharmaceutical Research Institute.
He graduated from the University of Maryland with a B.S. in zoology and George Washington University where he studied genetics.
Dr. Clay has also been recognized for his excellent work several times, being awarded the Pacific Northwest Ernst & Young Entrepreneur of the Year in 2012.